Evidence map›Paper›PMID 30044042›Full record

ArticleJournal of cellular and molecular medicine2018

MicroRNA-194 protects against chronic hepatitis B-related liver damage by promoting hepatocyte growth via ACVR2B.

Xue Gao, Pan Zhao, Jie Hu, Hongguang Zhu, Jiming Zhang, Zhongwen Zhou, Jingmin Zhao, Feng Tang

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Xue GaoDepartment of Pathology, 302 Hospital, Beijing, China.
Pan ZhaoClinical Trial Center, Beijing 302 Hospital, Beijing, China.
Jie HuLiver Surgery Department, Zhongshan Hospital, Fudan University, Shanghai, China.
Hongguang ZhuDepartment of Pathology, Shanghai Medical College, Fudan University, Shanghai, China.
Jiming ZhangDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Zhongwen ZhouDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Jingmin ZhaoDepartment of Pathology, 302 Hospital, Beijing, China.
Feng TangDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-0870-8890
302 Military Hospital of China · CNFudan University · CNShanghai Medical College of Fudan University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistent infection with the hepatitis B virus leads to liver cirrhosis and hepatocellular carcinoma. MicroRNAs (miRNAs) play an important role in a variety of biological processes; however, the role of miRNAs in chronic hepatitis B (CHB)-induced liver damage remains poorly understood. Here, we investigated the role of miRNAs in CHB-related liver damage. Microarray analysis of the expression of miRNAs in 22 CHB patients and 33 healthy individuals identified miR-194 as one of six differentially expressed miRNAs. miR-194 was up-regulated in correlation with increased liver damage in the plasma or liver tissues of CHB patients. In mice subjected to 2/3 partial hepatectomy, miR-194 was up-regulated in liver tissues in correlation with hepatocyte growth and in parallel with the down-regulation of the activin receptor ACVR2B. Overexpression of miR-194 in human liver HL7702 cells down-regulated ACVR2B mRNA and protein expression, promoted cell proliferation, acceleratedG1 to S cell cycle transition, and inhibited apoptosis, whereas knockdown of miR-194 had the opposite effects. Luciferase reporter assays confirmed that ACVR2B is a direct target of miR-194, and overexpression of ACVR2B significantly repressed cell proliferation and G1 to S phase transition and induced cell apoptosis. ACVR2B overexpression abolished the effect of miR-194, indicating that miR-194 promotes hepatocyte proliferation and inhibits apoptosis by down-regulating ACVR2B. Taken together, these results indicate that miR-194 plays a crucial role in hepatocyte proliferation and liver regeneration by targeting ACVR2B and may represent a novel therapeutic target for the treatment of CHB-related liver damage.

Indexed as

Activin Receptors, Type IIAnimalsBase SequenceCase-Control StudiesCell CycleCell ProliferationCells, CulturedGene Expression RegulationGenes, ReporterHepatitis B, ChronicHepatitis B virusHepatocytesHost-Pathogen InteractionsHumansLiverLiver RegenerationActivin Receptors, Type IIACVR2B protein, humanLuciferasesMicroRNAsMIRN194 microRNA, humanOligoribonucleotidesTumor Suppressor Protein p53ACVR2Bchronic hepatitis Bliver regenerationmicroRNAsmiR-194

Identifiers

PMID30044042
PMCPMC6111826
OpenAlexW2883308185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.